Concepedia

P. Fidias

PF

18

Publications

2.8K

Citations

16

H-Index

2000

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Massachusetts General Hospital

Harvard University

Brigham and Women's Hospital

Dana-Farber Brigham Cancer Center

P. Fidias is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

2000–2014

18

Publications

18

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations · Full text

, , +10

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

Frank V. Fossella, Jose R. Pereira, Joachim von Pawel et al. · Journal of Clinical Oncology · 2003 · 942 citations

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

Jennifer A. Chan, Lawrence S. Blaszkowsky, Peter C. Enzinger et al. · Annals of Oncology · 2011 · 107 citations · Full text

, , +11

Occult Primary

David S. Ettinger, Mark Agulnik, Justin Cates et al. · Journal of the National Comprehensive Cancer Network · 2011 · 60 citations · Full text

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

David P. Ryan, Leonard J. Appleman, Thomas J. Lynch et al. · Cancer · 2006 · 48 citations

Rows per page

1–5 of 18